Tetrandrine and adriamycin reverse multidrug resistance by regulating NLRP3/Caspase-1/GSDMD signaling in human breast cancer cells
European Journal of Pharmacology · 2025
DOI: 10.1016/j.ejphar.2025.177635 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025. Verfasst von Guosong Xin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center for Medicine, Harbin University of Commerce, Harbin, 150076, China; National Ministry of Education Anti-tumor Natural Dru…. Hauptthemen laut MEDLINE: Benzylisoquinolines, Drug Resistance, Neoplasm, Doxorubicin, Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Heilongjiang Province, Harbin University of Commerce.
Abstract (Originalsprache)
PURPOSE: This study examined the effects and underlying mechanisms of tetrandrine (TET) combined with adriamycin (ADR) in reversing multidrug resistance (MDR) in breast cancer cells. METHODS: Cell viability, proliferation, and drug resistance were assessed via the MTT assay. Small interfering RNA (siRNA) transfection was used to knock down GSDMD expression in MCF-7/ADR cells. Pyroptosis induction by the combined TET and ADR treatment was evaluated through morphological observations, cytotoxicity assays, and flow cytometry. The expression levels of mRNA and proteins were analyzed using qRT-PCR and western blotting, respectively. RESULTS: At non-cytotoxic concentrations, the combined treatment of TET and ADR significantly inhibited the growth of MCF-7/ADR cells, demonstrating a synergistic effect in reversing MDR. This combination effectively reduced MDR protein expression in MCF-7/ADR cells via GSDMD modulation, which diminished efflux activity and promoted ADR accumulation. The increased accumulation of ADR subsequently activated the NLRP3/Caspase-1/GSDMD signaling pathway, leading to elevated LDH release and enhanced pyroptosis rates. CONCLUSION: The combined use of TET and ADR not only suppresses MCF-7/ADR cell growth but also reverses MDR by targeting the NLRP3/Caspase-1/GSDMD pyroptosis pathway. These findings propose a promising therapeutic strategy for combatting MDR in breast cancer and highlight the potential for further clinical application of this combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engineering Research Center for Medicine, Harbin University of Commerce, Harbin, 150076, China; National Ministry of Education Anti-tumor Natural Drug Engineering Research Center, Harbin, 150076, China. Electronic addre…
- Engineering Research Center for Medicine, Harbin University of Commerce, Harbin, 150076, China.
- Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China. Electronic address: lihairu0419@126.com.
Förderung
- Natural Science Foundation of Heilongjiang Province
- Harbin University of Commerce
Zitieren
APA
Xin, G., Hou, Y., Liu, Y., & Li, H. (2025). Tetrandrine and adriamycin reverse multidrug resistance by regulating NLRP3/Caspase-1/GSDMD signaling in human breast cancer cells. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.177635
Vancouver
Xin G, Hou Y, Liu Y, Li H. Tetrandrine and adriamycin reverse multidrug resistance by regulating NLRP3/Caspase-1/GSDMD signaling in human breast cancer cells. European Journal of Pharmacology. 2025. doi:10.1016/j.ejphar.2025.177635
BibTeX
@article{Xin2025,
author = {Xin, Guosong and Hou, Yanxiu and Liu, Yuhan and Li, Hairu},
title = {Tetrandrine and adriamycin reverse multidrug resistance by regulating NLRP3/Caspase-1/GSDMD signaling in human breast cancer cells},
journal = {European Journal of Pharmacology},
year = {2025},
doi = {10.1016/j.ejphar.2025.177635}
}
EUVIMED